NASDAQ:IPSC Century Therapeutics (IPSC) Stock Price, News & Analysis $1.94 -0.09 (-4.43%) Closing price 04:00 PM EasternExtended Trading$1.94 0.00 (-0.26%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Century Therapeutics Stock (NASDAQ:IPSC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Century Therapeutics alerts:Sign Up Key Stats Today's Range$1.91▼$2.0350-Day Range$1.90▼$2.4352-Week Range$0.44▼$3.04Volume510,033 shsAverage Volume381,956 shsMarket Capitalization$351.28 millionP/E RatioN/ADividend YieldN/APrice Target$4.75Consensus RatingHold Company Overview Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays. The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates. Early-stage programs include iPSC-derived NK cell candidates engineered for enhanced tumor targeting and persistence, alongside T cell programs incorporating novel receptor constructs. Century has established strategic collaborations with leading pharmaceutical partners to advance preclinical research and prepare select programs for clinical evaluation. Founded in 2019 as a spin-out from the Wistar Institute and the University of Pennsylvania, Century Therapeutics is headquartered in Philadelphia. Since its inception, the company has built multidisciplinary teams across research, manufacturing and regulatory affairs. Century’s leadership brings experience from established biopharmaceutical companies and academic institutions, supporting its goal of delivering transformative cell therapies to patients worldwide.AI Generated. May Contain Errors. Read More Century Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreIPSC MarketRank™: Century Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 684th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCentury Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCentury Therapeutics has a consensus price target of $4.75, representing about 144.8% upside from its current price of $1.94.Amount of Analyst CoverageCentury Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Century Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Century Therapeutics are expected to grow in the coming year, from ($0.47) to ($0.43) per share.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Century Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.71% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 70.64, which indicates bearish sentiment.Change versus previous monthShort interest in Century Therapeutics has recently increased by 0.54%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.26 News SentimentCentury Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Century Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for IPSC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,066.00 in company stock.Percentage Held by Insiders2.40% of the stock of Century Therapeutics is held by insiders.Percentage Held by Institutions50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Century Therapeutics' insider trading history. Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IPSC Stock News HeadlinesCentury Therapeutics Appoints IECURE CEO Joseph Truitt To Board As CNTY-813 Nears IND FilingSeptember 10 at 7:46 AM | rttnews.comCentury Therapeutics Appoints Joseph Truitt to Board of DirectorsSeptember 9 at 4:05 PM | globenewswire.comShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline.September 10 at 1:00 AM | Chaikin Analytics (Ad)Century Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesAugust 12, 2026 | finanznachrichten.deCentury Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesAugust 12, 2026 | globenewswire.comCentury Therapeutics (IPSC) to Present CNTY-813 Data at Scientific CongressesJuly 14, 2026 | insidermonkey.comCentury: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative PotentialJuly 9, 2026 | seekingalpha.comCentury Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026July 9, 2026 | globenewswire.comSee More Headlines IPSC Stock Analysis - Frequently Asked Questions How have IPSC shares performed this year? Century Therapeutics' stock was trading at $0.9948 at the beginning of the year. Since then, IPSC shares have increased by 95.0% and is now trading at $1.94. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) announced its earnings results on Wednesday, August, 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.06. When did Century Therapeutics IPO? Century Therapeutics (IPSC) raised $200 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 10,550,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Century Therapeutics' major shareholders? Century Therapeutics' top institutional shareholders include BlackRock Inc. (4.49%), Seven Fleet Capital Management LP (2.41%), Trails Edge Capital Partners LP (2.29%) and Spruce Street Capital LP (2.25%). Insiders that own company stock include Brent Pfeiffenberger, Chad Cowan, Gregory Russotti, Douglas Carr and Adrienne Farid. View institutional ownership trends. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Century Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Century Therapeutics investors own include The RMR Group (RMR), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/12/2026Today9/10/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IPSC's financial health is in the Green zone, according to TradeSmith. IPSC has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IPSC CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees170Year Founded2018Price Target and Rating Average Price Target for Century Therapeutics$4.75 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+144.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.58 million Net MarginsN/A Pretax Margin-8.84% Return on Equity-49.51% Return on Assets-38.09% Debt Debt-to-Equity RatioN/A Current Ratio8.28 Quick Ratio8.28 Sales & Book Value Annual Sales$109.16 million Price / Sales3.22 Cash Flow$0.01 per share Price / Cash Flow152.63 Book Value$1.82 per share Price / Book1.07Miscellaneous Outstanding Shares181,070,000Free Float176,729,000Market Cap$351.28 million OptionableOptionable Beta1.59 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:IPSC) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
